Company Performance Metrics
Len Wechsler: Team Member
Brian Dresser: Co-Founder & VP Medical Research
Nuraleve™ has created proprietary medical protocols and software for use by medical professionals in the assessment and treatment of patients. Their PainRelief tc™ neurostimulator is designed for per-treatment billing to the physician, with no upfront fee to clinics for adopting the technology.
Other indications approved in Europe are Acute
Pain, Depression, Post-stroke rehabilitation, Cognitive Deficit, and Addiction Reduction including Obesity, Alcohol, Drugs (marijuana, cocaine, opioids, methamphetamines), and Smoking. Regulatory approvals are based upon clinical data including double-blind Randomized Controlled Trials (RCTs).
Nuraleve™ is now engaging with equity investors to fund PainRelief tc™ sales efforts in Europe, completion of the FDA process, and working capital to scale the business model.
